🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Health Catalyst, Inc. HCAT R2K

Healthcare · Health Information Services · United States
https://www.healthcatalyst.com

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

READ MORE ›
$1.38
-63.68% 1Y

Market & Price

Market Cap
$101.97M
Current Price
$1.38
High / Low (52W)
$4.16 / $1.00
Beta
1.63

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
14.95
PEG Ratio
-
Book Value
$1.87
Price to Book
0.74
P/S
0.34
EV/EBITDA
189.72
Dividend Yield
-

Profitability & Returns

ROCE
-37.04%
ROE
-103.02%
ROA
-3.48%
Profit Margin
-87.70%
Op Margin
-9.54%
EPS (Latest Qtr)
$-1.53
EPS (TTM)
$-3.73

Balance Sheet & Liquidity

Debt/Equity
1.23
Quick Ratio
1.56
Current Ratio
1.69
Debt
$170.58M
Total Assets
$502.64M
Current Assets
$169.31M
Working Capital
$79.73M

Ownership

Promoter Holding
5.29%
Chg in Prom Hold
-
FII / Inst Holding
79.03%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$163.73M
Total Revenue (TTM)
$302.48M
EBITDA
$863.00K
Free Cash Flow
$23.99M
Operating Cash Flow
$18.96M
Shares Outstanding
73.89M
Gross Margin
50.44%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
4.05%
Profit 5Y
-9.84%
Revenue (YoY)
-10.90%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -9.8% CAGR over 5 years.
  • Trading 66.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HCAT Health Catalyst, Inc. R2K 1.38 - $101.97M - -37.04% -103.02% 4.05% -9.84%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 22.99M32.87M35.21M36.80M39.42M45.12M43.26M47.19M55.85M59.63M61.74M68.09M70.63M68.35M73.87M73.21M73.77M74.72M75.90M76.35M79.41M80.72M76.32M74.68M70.76M
Cost of Revenue --------------------43.18M42.48M38.51M35.30M35.29M
Gross Profit -------------------36.29M36.23M38.24M37.82M39.38M35.46M
Operating Expenses --------------------53.25M46.57M55.33M36.12M42.63M
Operating Income -18.81M-16.50M-11.09M-9.36M-20.74M-18.11M-15.64M-23.46M-24.32M-32.32M-42.25M-24.35M-33.19M-45.72M-34.91M-34.62M-24.58M-22.81M-15.81M-13.69M-17.02M-8.32M-17.51M3.26M-7.16M
EBITDA ---------------------3.89M-22.43M-3.94M-72.25M-93.75M
Interest Expense --------------------7.32M5.79M5.63M5.52M4.74M
Pretax Income ---------------------23.53M-40.90M-22.19M-90.65M-110.61M
Tax Provision --------------------215.00K81.00K41.00K379.00K414.00K
Net Income -19.32M-16.88M-13.72M-10.69M-21.42M-17.49M-27.18M-27.33M-28.37M-35.83M-40.01M-22.46M-33.43M-45.73M-33.19M-32.61M-22.03M-20.59M-13.52M-14.73M-23.74M-40.98M-22.23M-91.03M-111.03M
Diluted EPS ------0.47-0.71-0.68-0.65-0.80-0.82-0.54-0.62-0.84-0.60-0.58-0.39-0.35-0.23-0.24-0.35-0.59-0.32-1.28-1.53
R&D Expense 8.49M10.84M10.02M9.71M13.48M13.09M12.06M13.39M14.35M14.52M16.39M17.15M18.15M20.77M17.08M17.59M17.67M14.87M13.88M14.19M15.19M12.39M12.28M-9.78M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 73.08M112.57M154.94M188.84M-276.24M295.94M306.58M311.14M
Cost of Revenue -----143.05M164.10M165.81M159.46M
Gross Profit -----133.19M131.83M140.78M151.68M
Operating Expenses -----273.19M231.83M198.39M194.42M
Operating Income -45.54M-60.09M-54.87M-96.12M--140.00M-100.00M-57.61M-42.74M
EBITDA ------91.71M-57.78M-10.65M-102.50M
Interest Expense -----7.24M7.29M17.09M24.25M
Pretax Income ------141.68M-117.79M-69.17M-177.26M
Tax Provision ------4.28M356.00K333.00K716.00K
Net Income -47.03M-61.98M-60.10M-115.02M--137.40M-118.15M-69.50M-177.97M
Diluted EPS ---12.86-2.91--2.63-2.09-1.15-2.55
R&D Expense 28.47M38.59M46.25M53.52M62.73M75.68M72.63M57.95M49.77M

Compounded Sales Growth

5 Years:4.05%
1 Year:-10.90%

Compounded Profit Growth

5 Years:-9.84%
1 Year:-

Stock Price Performance

1 Year:-63.68%
6 Months:-50.18%
3 Months:-14.81%
1 Month:+8.66%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --110.97M302.36M577.74M-752.29M701.81M858.93M502.64M
Current Assets ------427.80M393.40M465.65M169.31M
Cash & Equivalents --28.43M18.03M91.95M-116.31M106.28M249.65M50.81M
Inventory ----------
Receivables ------47.97M60.29M57.18M59.13M
Total Liabilities --75.90M101.72M301.64M-327.28M334.89M493.72M256.86M
Current Liabilities --41.81M48.22M88.04M-82.51M89.03M325.85M89.57M
Long Term Debt --18.81M48.20M168.99M-226.52M228.03M151.18M151.62M
Total Debt ------247.97M249.07M402.26M171.24M
Total Equity -206.41M-259.48M-374.77M200.64M276.10M-425.01M366.92M365.21M245.78M
Shares Outstanding ------55.26M58.30M64.04M72.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -36.83M-40.30M-32.18M-26.15M--35.27M-33.08M14.56M731.00K
Investing Cash Flow 22.41M21.40M-209.60M-82.56M--39.02M20.29M-22.90M36.19M
Financing Cash Flow 24.87M24.35M231.38M182.61M--2.61M2.73M151.75M-235.78M
Capital Expenditure -2.47M-2.08M-2.02M-7.78M--17.41M-14.31M-16.40M-21.55M
Free Cash Flow -39.30M-42.37M-34.20M-33.92M--52.68M-47.39M-1.84M-20.82M
Net Change in Cash ------76.90M-10.06M143.40M-198.86M
Share Buybacks 08.71M0008.39M1.81M05.00M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----48.2%44.5%45.9%48.7%
Operating Margin % -62.3%-53.4%-35.4%-50.9%--50.7%-33.8%-18.8%-13.7%
Net Margin % -64.4%-55.1%-38.8%-60.9%--49.7%-39.9%-22.7%-57.2%
ROE % 18.1%16.5%-30.0%-41.7%--32.3%-32.2%-19.0%-72.4%
ROCE % --86.9%-21.6%-19.6%--20.9%-16.3%-10.8%-10.3%

Shareholding Pattern

Insiders
5.29%
Institutions
79.03%
Public Float
83.44%

Top Institutional Holders

#Holder% HeldSharesValue
1 First Light Asset Management, LLC 17.43% 12.88M $17.77M
2 Cdc Financial, Inc. 8.54% 6.31M $8.70M
3 Blackrock Inc. 6.95% 5.14M $7.09M
4 Whetstone Capital Advisors, LLC 5.78% 4.27M $5.89M
5 Palogic Value Management, LP 3.92% 2.90M $4.00M
6 Vanguard Capital Management LLC 3.91% 2.89M $3.98M
7 Impax Asset Management Group plc 3.72% 2.75M $3.79M
8 Nepsis, Inc. 2.54% 1.88M $2.59M
9 Geode Capital Management, LLC 2.03% 1.50M $2.07M
10 State Street Corporation 1.79% 1.32M $1.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HCAT

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks